ReviewFrontiers in immunology2014
Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Preliminary Study on Type I Interferon as a Mucosal Adjuvant for Human Respiratory Syncytial Virus F Protein.Vaccines · 2024Article
- Feasibility of Using a Type I IFN-Based Non-Animal Approach to Predict Vaccine Efficacy and Safety Profiles.Vaccines · 2024Review
- Upregulation of IFNE in cervical biopsies of patients with high-risk human papillomavirus infections.Immunity, inflammation and disease · 2023Article
- Interferon epsilon and preterm birth subtypes; a new piece of the type I interferon puzzle during pregnancy?American journal of reproductive immunology (New York, N.Y. : 1989) · 2022Article
- The regulation of antiviral activity of interferon epsilon.Frontiers in microbiology · 2022Review
- Article
- Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Oncogene · 2017Article
- Effects of interferons and double-stranded RNA on human prostate cancer cell apoptosis.Oncotarget · 2015Article
- IL-4 Induced Innate CD8+ T Cells Control Persistent Viral Infection.PLoS pathogens · 2015Article
- Type I IFN family members: similarity, differences and interaction.Cytokine & growth factor reviews · 2015Review
- Interferons and viruses: an evolutionary arms race of molecular interactions.Trends in immunology · 2015Review
- Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.Protein & cell · 2015Review
- Mysteries of type I IFN response: benefits versus detriments.Frontiers in immunology · 2015Article
- Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been well-established that type I interferons (IFN-Is) have pleiotropic effects and play an early central role in the control of many acute viral infections. However, their pleiotropic effects are not always beneficial to the host and in fact several reports suggest that the induction of IFN-Is exacerbate disease outcomes against some bacterial and chronic viral infections. In this brief review, we probe into this mystery and try to develop answers based on past and recent studies evaluating the roles of IFN-Is in infection and immunity as this is vital for developing effective IFN-Is based therapeutics and vaccines. We also discuss the biological roles of an emerging IFN-I, namely IFN-ε, and discuss its potential use as a mucosal therapeutic and/or vaccine adjuvant. Overall, we anticipate the discussions generated in this review will provide new insights for better exploiting the biological functions of IFN-Is in developing efficacious therapeutics and vaccines in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.